Stock listing
Dusseldorf:1C0 Celyad Oncology SA Aktie
German listing (Dusseldorf) of Celyad Oncology SA · home listing Euronext:CYAD
Follow Celyad Oncology SA into a list and get an email when it puts out news.
Home listing price · EURONEXT:CYAD
€0.162 EUR -0.013 (-7.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:CYAD
- Day range
- €0.145 – €0.163 EURNov 20, 2026
- Volume
- 4,985 sharesNov 20, 2026
- Market cap
- €12.13M EURAt the close on Nov 20, 2026 · price × 74.88M shares outstanding
- 52-week range
- €0.140 – €0.650 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €2,960 EURMedian day 9,914 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:CYAD · Home | €0.162 EUR | -0.013 (-7.4%) | 4,985 | €0.161 | €0.163 | €0.145 | €0.175 | Close on Nov 20, 2026 |
| Frankfurt:1C0 | €0.121 EUR | 0.000 (0.0%) | — | €0.121 | €0.121 | €0.121 | €0.121 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:CYAD · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.162 | -0.013 | -7.4% | €0.161 | €0.163 | €0.145 | 4,985 | |
| €0.175 | +0.025 | +16.7% | €0.169 | €0.175 | €0.167 | 10,933 | |
| €0.150 | +0.010 | +7.1% | €0.146 | €0.150 | €0.145 | 74,368 | |
| €0.140 | -0.026 | -15.7% | €0.160 | €0.160 | €0.140 | 34,974 | |
| €0.166 | -0.004 | -2.4% | €0.151 | €0.170 | €0.151 | 11,404 | |
| €0.170 | -0.009 | -5.0% | €0.170 | €0.171 | €0.165 | 44,987 | |
| €0.179 | +0.009 | +5.3% | €0.170 | €0.179 | €0.170 | 34,842 | |
| €0.170 | -0.010 | -5.6% | €0.180 | €0.180 | €0.170 | 16,195 | |
| €0.180 | +0.002 | +1.1% | €0.178 | €0.180 | €0.171 | 13,540 | |
| €0.178 | -0.002 | -1.1% | €0.180 | €0.180 | €0.171 | 18,433 | |
| €0.180 | -0.003 | -1.6% | €0.180 | €0.189 | €0.170 | 43,613 | |
| €0.183 | -0.013 | -6.6% | €0.193 | €0.193 | €0.180 | 15,856 | |
| €0.196 | -0.004 | -2.0% | €0.197 | €0.198 | €0.193 | 3,839 | |
| €0.200 | 0.000 | 0.0% | €0.200 | €0.210 | €0.200 | 11,195 | |
| €0.200 | -0.010 | -4.8% | €0.206 | €0.206 | €0.200 | 6,719 | |
| €0.210 | 0.000 | 0.0% | €0.210 | €0.210 | €0.206 | 853 | |
| €0.210 | 0.000 | 0.0% | €0.206 | €0.210 | €0.206 | 12,282 | |
| €0.210 | +0.003 | +1.4% | €0.206 | €0.210 | €0.206 | 11,777 | |
| €0.207 | -0.017 | -7.6% | €0.220 | €0.220 | €0.207 | 1,249 | |
| €0.224 | +0.016 | +7.7% | €0.206 | €0.224 | €0.206 | 1,731 | |
| €0.208 | -0.017 | -7.6% | €0.208 | €0.208 | €0.208 | 8 | |
| €0.225 | +0.015 | +7.1% | €0.206 | €0.225 | €0.206 | 8,431 | |
| €0.210 | +0.004 | +1.9% | €0.225 | €0.225 | €0.210 | 221 | |
| €0.206 | -0.021 | -9.3% | €0.205 | €0.224 | €0.205 | 1,277 | |
| €0.227 | +0.013 | +6.1% | €0.213 | €0.228 | €0.205 | 11,850 | |
| €0.214 | +0.008 | +3.9% | €0.206 | €0.214 | €0.206 | 9,667 | |
| €0.206 | -0.014 | -6.4% | €0.220 | €0.220 | €0.206 | 4,359 | |
| €0.220 | +0.010 | +4.8% | €0.230 | €0.230 | €0.210 | 15,270 | |
| €0.210 | +0.010 | +5.0% | €0.210 | €0.220 | €0.210 | 1,906 | |
| €0.200 | -0.030 | -13.0% | €0.200 | €0.200 | €0.200 | 430 | |
| €0.230 | +0.011 | +5.0% | €0.219 | €0.230 | €0.200 | 26,697 | |
| €0.219 | -0.001 | -0.5% | €0.219 | €0.225 | €0.219 | 6,792 | |
| €0.220 | 0.000 | 0.0% | €0.219 | €0.229 | €0.219 | 3,605 | |
| €0.220 | -0.005 | -2.2% | €0.220 | €0.230 | €0.219 | 19,748 | |
| €0.225 | +0.005 | +2.3% | €0.220 | €0.229 | €0.220 | 7,218 | |
| €0.220 | -0.001 | -0.5% | €0.224 | €0.229 | €0.220 | 43,440 | |
| €0.221 | -0.007 | -3.1% | €0.228 | €0.228 | €0.221 | 16,683 | |
| €0.228 | +0.003 | +1.3% | €0.229 | €0.229 | €0.220 | 10,048 | |
| €0.225 | -0.010 | -4.3% | €0.234 | €0.235 | €0.220 | 20,948 | |
| €0.235 | -0.014 | -5.6% | €0.234 | €0.250 | €0.234 | 12,368 | |
| €0.249 | 0.000 | 0.0% | €0.250 | €0.250 | €0.235 | 5,655 | |
| €0.249 | +0.018 | +7.8% | €0.231 | €0.254 | €0.231 | 8,084 | |
| €0.231 | -0.019 | -7.6% | €0.235 | €0.263 | €0.231 | 18,663 | |
| €0.250 | +0.010 | +4.2% | €0.230 | €0.250 | €0.230 | 3,306 | |
| €0.240 | -0.001 | -0.4% | €0.230 | €0.241 | €0.230 | 785 | |
| €0.241 | +0.001 | +0.4% | €0.258 | €0.264 | €0.237 | 33,511 | |
| €0.240 | -0.023 | -8.7% | €0.239 | €0.245 | €0.230 | 4,026 | |
| €0.263 | +0.037 | +16.4% | €0.248 | €0.266 | €0.230 | 17,077 | |
| €0.226 | -0.034 | -13.1% | €0.260 | €0.260 | €0.226 | 38,279 | |
| €0.260 | 0.000 | 0.0% | €0.260 | €0.272 | €0.260 | 667 | |
| €0.260 | -0.013 | -4.8% | €0.260 | €0.272 | €0.260 | 683 | |
| €0.273 | +0.011 | +4.2% | €0.262 | €0.273 | €0.260 | 9,779 | |
| €0.262 | -0.011 | -4.0% | €0.274 | €0.274 | €0.261 | 2,057 | |
| €0.273 | +0.013 | +5.0% | €0.260 | €0.273 | €0.260 | 2,163 | |
| €0.260 | -0.001 | -0.4% | €0.273 | €0.273 | €0.260 | 1,335 | |
| €0.261 | -0.012 | -4.4% | €0.260 | €0.261 | €0.260 | 282 | |
| €0.273 | -0.001 | -0.4% | €0.260 | €0.273 | €0.260 | 1,539 | |
| €0.274 | +0.013 | +5.0% | €0.261 | €0.274 | €0.261 | 1,369 | |
| €0.261 | 0.000 | 0.0% | €0.261 | €0.269 | €0.261 | 15,919 | |
| €0.261 | -0.010 | -3.7% | €0.270 | €0.270 | €0.261 | 8,559 | |
| €0.271 | +0.010 | +3.8% | €0.277 | €0.277 | €0.260 | 22,588 | |
| €0.261 | +0.004 | +1.6% | €0.273 | €0.278 | €0.256 | 21,999 | |
| €0.257 | -0.005 | -1.9% | €0.256 | €0.278 | €0.255 | 32,008 | |
| €0.262 | -0.016 | -5.8% | €0.256 | €0.275 | €0.256 | 4,849 | |
| €0.278 | -0.003 | -1.1% | €0.271 | €0.284 | €0.255 | 36,512 | |
| €0.281 | +0.008 | +2.9% | €0.275 | €0.287 | €0.270 | 28,243 |
- Ticker
- Dusseldorf:1C0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Sep 23, 2026
Celyad Oncology Reports First Half Year 2026 Results
Latest news
Celyad Oncology Reports First Half Year 2026 Results
Sep 23, 2026
Closed €0.249 (0.0%) on Sep 24, 2026
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Jul 22, 2026
Closed €0.264 (+5.6%) on Jul 23, 2026
Celyad Oncology Announces €500,000 Private Placement
Jul 14, 2026
Closed €0.25 (+1.6%) on Jul 14, 2026
Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights
Apr 2, 2026
Closed €0.328 (+2.5%) on Apr 7, 2026
Celyad Oncology Announces the Sale of C-CATHez ® Catheter
Feb 12, 2026
Closed €0.272 (+23.1%) on Feb 12, 2026
Celyad Oncology SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 25 in all · newest Sep 23, 2026 · oldest 2023
- Decks
- 28 decks · latest January 2023
Where Celyad Oncology SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:CYAD · Home listing | Euronext | Belgium | EUR |
| LS Exchange:A1W7Q9 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W7Q9 | Lang & Schwarz | Germany | EUR |
| LSE:0QFK | LSE | United Kingdom | EUR |
| OTC:CLYYF | OTC | United States | USD |
| Turquoise:CYADB | Turquoise | United Kingdom | EUR |
| Aquis:CYADB | Aquis | United Kingdom | EUR |
| Aquis:CYADB | Aquis | United Kingdom | EUR |
| Dusseldorf:1C0 · This page | Dusseldorf | Germany | EUR |
| Frankfurt:1C0 | Frankfurt | Germany | EUR |
| Munich:1C0 | Munich | Germany | EUR |
| Stuttgart:1C0 | Stuttgart | Germany | EUR |
Valuation
P/E 14.6× against a median of 0.3×: the highest of 2 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €12.04M EUR
- P/E
- 14.6×
- EV/sales
- 573×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 9.7×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| BioInvent International AB · OMXSTO:BINV | US$13.48M | −US$6.64M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.48M | US$15.05M | n/a | n/a | 52.7× | 3.6× | n/a | 0.4× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.24M | −US$16.69M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Median of the others | US$13.42M | US$11.45M | 0.3× | 2.2× | 52.7× | 0.9× | −204.1% | 0.0× | 1.38 |
Team and board
Officers
| Officer | Role |
|---|---|
| Hannes Iserentant | General Manager |
Board
| Director | Role |
|---|---|
| Hilde Windels | Chairwoman of the Board |
| Christopher LiPuma | Non-Executive Director |
| Dominic Piscitelli | Independent Director |
| Jonathan James | Non-Executive Director |
| Marina Udier | Independent Director |
| Matt Kane | Non-Executive Director |
| Michel Lussier | Non-Executive Director |
| Sage Mandel | Non-Executive Director |
| Serge Goblet | Non-Executive Director |
| Sharon Roberg-Perez | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Mar 19, 2026 | −2.6% |
| Q2 2025 | Sep 25, 2025 | +2.0% |
| Q2 2024 | Sep 13, 2024 | +0.6% |
| Q2 2023 | Sep 4, 2023 · After close | −8.1% |
| Q4 2022 | Mar 23, 2023 · After close | +4.8% |
| Q2 2022 | Aug 5, 2022 · Before open | +3.1% |
| Q4 2021 | Mar 24, 2022 | −7.3% |
| Q2 2021 | Aug 4, 2021 | +0.6% |
| Q4 2020 | Mar 24, 2021 | −3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2023) | Investor deck | 15 slides | January 2023 |
| Fact Sheet (June 2022) | Fact sheet | 2 slides | Jun 27, 2022 |
| Fact Sheet (June 2022) | Fact sheet | 1 slide | June 2022 |
| Fact Sheet (May 2022) | Fact sheet | 2 slides | May 4, 2022 |
| Fact Sheet (May 2022) | Fact sheet | 2 slides | May 4, 2022 |
| Fact Sheet (May 2022) | Fact sheet | 1 slide | May 4, 2022 |
| Corporate Update (December 2021) | Corporate update | 28 slides | Dec 13, 2021 |
| William Blair Growth Stock Conference 2021 | Conference | 51 slides | Jul 20, 2021 |
| European Hematology Association Virtual Congress 2021 | Conference | 24 slides | Jun 11, 2021 |
| European Hematology Association Virtual Congress 2021 | Conference | 23 slides | Jun 11, 2021 |
All 28 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of capital increase (shares) Closed: €500,000 raised · €0.2 a share Buyers: CFIP CLYD (UK) Limited (€500,000 for 2,500,000 shares; expected to hold approximately 60.52% of outstanding shares and approximately 68.75% of voting rights); an affiliate of Fortress Investment Group (2,500,000 new shares) Insiders: Fortress, a related party through its shareholding and board representation, is the subscriber; its nominated directors did not take part in the board deliberations or votes. Use of proceeds: Working capital and general corporate purposes | Sep 23, 2026 | US$569,630 |
| Private placement of newly issued ordinary shares Announced: €1M · €0.3 a share Buyers: CFIP CLYD (UK) Limited (€1 million for 3,333,333 newly issued ordinary shares; expected to hold approximately 58.51% of the Company's shares) Insiders: Fortress, a related party of the Company, is the sole subscriber and is expected to hold approximately 58.51% of the shares Use of proceeds: Working capital for general corporate purposes; extend cash runway to mid Q4 2025 | Jul 28, 2025 | US$1.16M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.0K | 186.0K | 102.0K | 0 | 0 | 5.00K | 6.00K | 3.12M | 3.54M | 10.0M |
| Cost of revenue | -1.91M | 12.0K | 69.0K | 0 | 0 | 0 | 0 | 0 | 515.0K | 1.54M |
| Gross profit | 1.93M | 173.0K | 33.0K | 0 | 0 | 5.00K | 6.00K | 3.12M | 3.02M | 8.47M |
| Research and development | 3.28M | 3.23M | 4.60M | 18.9M | 20.8M | 21.5M | 25.2M | 23.6M | 22.9M | 27.7M |
| Selling, general and administrative | 1.70M | 3.20M | 6.03M | 10.5M | 9.91M | 9.31M | 8.72M | 9.01M | 9.31M | 9.74M |
| Operating income | -7.18M | -5.86M | -8.46M | -40.9M | -26.4M | -17.0M | -28.9M | -38.2M | -52.9M | -25.6M |
| Depreciation and amortization | 172.0K | 347.0K | 285.0K | 827.0K | 1.30M | 1.64M | 1.79M | 1.11M | 9.00M | 1.52M |
| EBITDA | -7.01M | -5.51M | -8.17M | -40.0M | -25.1M | -15.4M | -27.1M | -37.1M | -43.9M | -24.1M |
| Interest expense | 64.0K | 119.0K | 84.0K | 198.0K | 255.0K | 434.0K | 343.0K | 62.0K | 144.0K | 109.0K |
| Income before tax | -656.0K | -5.82M | -8.51M | -40.9M | -26.5M | -17.2M | -28.6M | -37.4M | -56.4M | -23.6M |
| Income tax | -1.49M | 0 | -63.0K | 65.0K | 10.0K | 0 | -8.00K | -1.11M | -1.00K | -6.00K |
| Net income | 830.0K | -5.82M | -8.45M | -40.9M | -26.5M | -17.2M | -28.6M | -37.4M | -56.4M | -23.6M |
| Earnings per share, basic | 0.02 | -0.14 | -0.34 | -1.81 | -1.70 | -1.23 | -2.29 | -3.36 | -5.86 | -2.53 |
| Earnings per share, diluted | -0.14 | -0.34 | -1.81 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.71M | 4.20M | 7.00M | 12.4M | 30.0M | 17.2M | 39.3M | 40.5M | 23.3M | 48.4M |
| Short-term investments | 0 | 0 | 0 | 0 | 9.20M | 10.7M | 34.2M | |||
| Receivables | 792.0K | 170.0K | 457.0K | 1.12M | 668.0K | 615.0K | 2.70M | 1.27M | 81.0K | 1.11M |
| Inventory | 0 | 417.0K | 1.26M | 1 | -2.14M | 1.56M | 1 | 1 | 1 | 642.0K |
| Current assets | 3.50M | 6.51M | 11.1M | 14.8M | 34.3M | 19.7M | 42.8M | 51.7M | 36.4M | 85.4M |
| Property, plant and equipment | 1.49M | 1.83M | 309.0K | 3.25M | 4.12M | 5.06M | 3.01M | 3.29M | 3.56M | |
| Goodwill | 0 | 0 | 342.0K | 0 | 883.0K | 883.0K | 883.0K | 883.0K | 914.0K | 1.04M |
| Total assets | 4.30M | 9.93M | 16.3M | 19.7M | 79.9M | 66.1M | 89.8M | 94.3M | 77.6M | 138.8M |
| Accounts payable | 511.0K | 1.23M | 1.24M | 4.75M | 6.61M | 4.74M | 6.97M | 5.92M | 4.80M | 8.10M |
| Current liabilities | 1.82M | 2.85M | 2.93M | 10.4M | 13.8M | 11.8M | 11.9M | 9.65M | 7.95M | 11.3M |
| Long-term debt | 0 | 0 | 0 | 37.0K | 229.0K | 326.0K | 536.0K | |||
| Total debt | 17.5M | 1.06M | 0 | 0 | 37.0K | 4.36M | 1.65M | 1.44M | 1.48M | |
| Total liabilities | 1.86M | 26.0M | 9.98M | 15.4M | 36.3M | 35.1M | 44.2M | 38.7M | 30.1M | 47.9M |
| Shareholders' equity | 2.44M | 511.0K | 6.30M | 4.32M | 31.0M | 31.0M | 45.6M | 55.6M | 47.5M | 90.9M |
| Shares outstanding | 46.3M | 41.4M | 25.7M | 22.6M | 15.6M | 13.9M | 12.5M | 11.1M | 9.62M | 9.33M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.90M | -5.68M | -15.2M | -28.0M | -26.6M | -27.7M | -28.2M | -27.2M | -49.5M | -24.7M |
| Capital spending | 0 | 0 | -899.0K | -123.0K | -331.0K | -150.0K | -622.0K | -1.76M | -858.0K | -1.78M |
| Free cash flow | -6.90M | -5.68M | -16.1M | -28.1M | -27.0M | -27.8M | -28.8M | -29.0M | -50.4M | -26.5M |
| Cash from investing | 3.01M | -103.0K | 407.0K | 7.20M | -126.0K | 157.0K | 8.99M | 607.0K | 22.7M | -30.2M |
| Cash from financing | 1.39M | 2.98M | 9.36M | 3.24M | 39.5M | 5.40M | 18.3M | 43.9M | 605.0K | 3.03M |
| Share buybacks | -124.0K | 16.4M | 43.0M | 625.0K | 751.0K | |||||
| Change in cash | -2.49M | -2.80M | -5.44M | -17.6M | 12.8M | -22.1M | -1.20M | 17.3M | -25.1M | -51.8M |
Cap table
Built by 6ix from Celyad Oncology SA’s releases · as of Sep 23, 2026
- Common shares
- 74,883,166
- Fully diluted
- 74,883,166
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 74,883,166 | Jul 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Jul 16, 2026 | 74,883,166 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher LiPuma | Non-Executive Director · Since at least Nov 5, 2026 |
| Dominic Piscitelli | Independent Director · Since at least Nov 5, 2026 |
| Hannes Iserentant | General Manager · Since at least Sep 23, 2026 |
| Hilde Windels | Chairwoman of the Board · Since at least Nov 5, 2026 |
| Jonathan James | Non-Executive Director · Since at least Nov 5, 2026 |
| Marina Udier | Independent Director · Since at least Nov 5, 2026 |
| Matthew Kane | Non-Executive Director · Since at least Aug 26, 2025 |
| Michel Lussier | Non-Executive Director · Since at least Nov 5, 2026 |
| Rue André Dumont | Investor Relations · Apr 18, 2025 – Nov 5, 2026 · Past |
| Sage Mandel | Non-Executive Director · Since at least Nov 5, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Serge Goblet | Non-Executive Director · Since at least Nov 5, 2026 |
| Sharon Roberg-Perez | Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Celyad Oncology SA.